-+ 0.00%
-+ 0.00%
-+ 0.00%

Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors

Benzinga·03/09/2026 12:48:30
Listen to the news

The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic signaling beyond the threshold achieved with RAS inhibition alone.